Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease.
Wooddell CI, Blomenkamp K, Peterson RM, Subbotin VM, Schwabe C, Hamilton J, Chu Q, Christianson DR, Hegge JO, Kolbe J, Hamilton HL, Branca-Afrazi MF, Given BD, Lewis DL, Gane E, Kanner SB, Teckman JH. Wooddell CI, et al. Among authors: lewis dl. JCI Insight. 2020 Jun 18;5(12):e135348. doi: 10.1172/jci.insight.135348. JCI Insight. 2020. PMID: 32379724 Free PMC article.
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection.
Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, Hegge JO, Klein JJ, Wakefield DH, Oropeza CE, Deckert J, Roehl I, Jahn-Hofmann K, Hadwiger P, Vornlocher HP, McLachlan A, Lewis DL. Wooddell CI, et al. Among authors: lewis dl. Mol Ther. 2013 May;21(5):973-85. doi: 10.1038/mt.2013.31. Epub 2013 Feb 26. Mol Ther. 2013. PMID: 23439496 Free PMC article.
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL. Wooddell CI, et al. Among authors: lewis dl. Sci Transl Med. 2017 Sep 27;9(409):eaan0241. doi: 10.1126/scitranslmed.aan0241. Sci Transl Med. 2017. PMID: 28954926 Free PMC article. Clinical Trial.
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.
Wong SC, Cheng W, Hamilton H, Nicholas AL, Wakefield DH, Almeida A, Blokhin AV, Carlson J, Neal ZC, Subbotin V, Zhang G, Hegge J, Bertin S, Trubetskoy VS, Rozema DB, Lewis DL, Kanner SB. Wong SC, et al. Among authors: lewis dl. Mol Cancer Ther. 2018 Jan;17(1):140-149. doi: 10.1158/1535-7163.MCT-17-0471. Epub 2017 Oct 27. Mol Cancer Ther. 2018. PMID: 29079709
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.
Schluep T, Lickliter J, Hamilton J, Lewis DL, Lai CL, Lau JY, Locarnini SA, Gish RG, Given BD. Schluep T, et al. Among authors: lewis dl. Clin Pharmacol Drug Dev. 2017 Jul;6(4):350-362. doi: 10.1002/cpdd.318. Epub 2016 Dec 12. Clin Pharmacol Drug Dev. 2017. PMID: 27739230 Free PMC article. Clinical Trial.
Protease-triggered siRNA delivery vehicles.
Rozema DB, Blokhin AV, Wakefield DH, Benson JD, Carlson JC, Klein JJ, Almeida LJ, Nicholas AL, Hamilton HL, Chu Q, Hegge JO, Wong SC, Trubetskoy VS, Hagen CM, Kitas E, Wolff JA, Lewis DL. Rozema DB, et al. Among authors: lewis dl. J Control Release. 2015 Jul 10;209:57-66. doi: 10.1016/j.jconrel.2015.04.012. Epub 2015 Apr 14. J Control Release. 2015. PMID: 25886706 Free article.
136 results